Skip to Main

John Gooch is the Regional Health Care lead for Europe, Middle East, South America, and Africa (EMESA) at Boston Consulting Group. He joined BCG in London in 1996 and has also spent time working in the New York and Paris offices.

John specializes in driving large programs focused on commercial and operational effectiveness, as well as setting up program management offices and systems.

He has broad experience in the global pharmaceutical sector, where his client engagements have covered R&D, operations, and commercial topics—particularly working with first-line leaders on both manufacturing and sales teams. He has also supported numerous post-merger integrations in the pharmaceutical industry.

In addition, John has led work with some of the world's leading hospitals inside and outside the National Health Service, and he has significant experience in consumer health care.

AREAS OF EXPERTISE

EDUCATION

  • PhD, Trinity College, Cambridge
  • MEng, first class honors, Imperial College London

HONORS AND AWARDS

  • Scholarship, ICI
  • Scholarship, Royal Academy of Engineering

Publications and Videos

" "

The Inflation Reduction Act’s Ripple Effects on the US Health Care Ecosystem

The IRA provisions concerning the pricing of drugs for Medicare patients are creating new economic realities for health care players.
" "

Unlocking the Potential of AI in Drug Discovery

This report examines AI's potential in drug discovery, exploring key applications, assessing maturity, identifying barriers, and proposing solutions. It emphasizes the crucial role of health research funders in shaping this dynamic field to address urgent health needs equitably.

Ramping Up Vaccine Manufacturing in Africa | rectangle

Ramping Up Vaccine Manufacturing in Africa

Stakeholder support is crucial for ensuring that African vaccine-manufacturing companies can produce sufficient supply for the continent.
Building-Health-Tech-Advantage-hero-rectangle (1).jpg

Building Health Tech Advantage

To deliver superior outcomes at scale, companies need to invest in ecosystems. Forging strong connections with patients and partners will be key.
" "

Vaccines to tackle drug resistant infections

Antimicrobial resistance is difficult to combat. This report gives a comprehensive assessment of vaccine R&D potential against pathogens with high levels of AMR.
Three medical professionals smiling at one another

Health Care Providers in Europe Need to Boost Digital Momentum

European health care companies struggle with digital maturity. We have identified four reasons for this, and key success factors for addressing these challenges.
a-post-covid-paradigm-shift-in-outpatient-care-rectangle-tcm9-247461.jpg

A Post-COVID Paradigm Shift in Outpatient Care

The pandemic has triggered a revolution in how health systems deliver care. It’s time to build on that momentum and make long-lasting improvements.
biopharma-cost-performance-1694x950-tcm9-164083.jpg

What Does—and Does Not—Drive Biopharma Cost Performance

A new approach reveals that scale is the most important cost factor in biopharma, but one kind of scale stands out for its contribution to cost reduction.
2013-twin-track-challenge-for-biopharma-executives-1116x626-tcm9-95690.jpg

The Twin-Track Challenge for Biopharma Executives

Biopharmaceutical companies can achieve substantial gains by adopting a “twin track” mindset: improve the current go-to-market strategy while developing new models.